1-6 of 6
Eric H. Westin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors

Juniper A. Scribner, Stuart W. Hicks, Kerstin W. Sinkevicius, Nicholas C. Yoder, Gundo Diedrich, Jennifer G. Brown, Jacquelynn Lucas, Megan E. Fuller, Thomas Son, Anahita Dastur, Jeff Hooley, Christopher W. Espelin, Marian Themeles, Francine Z. Chen, Ying Li, Michael Chiechi, Jenny Lee, Bhaswati Barat, Lusiana Widjaja, Sergey Gorlatov, James Tamura, Valentina Ciccarone, Olga Ab, Kerry A. McEachem, Scott Koenig, Eric H. Westin, Paul A. Moore, Thomas Chittenden, Richard J. Gregory, Ezio Bonvini, Deryk Loo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther molcanther.0915.2021.
DOI: https://doi.org/10.1158/1535-7163.MCT-21-0915
Published: 05 May 2022
View article
PDF
Includes: Supplementary data
Journal Articles

A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models

Xiang S. Ye, Li Fan, Robert D. Van Horn, Ryuichiro Nakai, Yoshihisa Ohta, Shiro Akinaga, Chikara Murakata, Yoshinori Yamashita, Tinggui Yin, Kelly M. Credille, Gregory P. Donoho, Farhana F. Merzoug, Heng Li, Amit Aggarwal, Kerry Blanchard, Eric H. Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (11): 2463–2472.
DOI: https://doi.org/10.1158/1535-7163.MCT-15-0241
Published: 03 November 2015
View article
PDF
Includes: Supplementary data
Journal Articles

Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.

Jeffrey R. Infante, Josep Tabernero, Andres Cervantes, Shadia Jalal, Howard A. Burris, Teresa Macarulla, J. Alejandro Perez-Fidalgo, Rachel Neuwirth, Chirag Patel, Esha Gangolli, Rachael Brake, Jeffrey Sturm, Eric H. Westin, Michael Gordon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C252.
DOI: https://doi.org/10.1158/1535-7163.TARG-13-C252
Published: 01 November 2013
View article
Journal Articles

Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors.

Victoria L. Peek, Suzane L. Um, S. Betty Yan, Lei Yan, Jack Dempsey, Darlene Barnard, Connie King, Darryl Ballard, Kathleen Heinz-Taheny, Mark Marshall, Richard Beckmann, Aimee Bence, Eric H. Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A49.
DOI: https://doi.org/10.1158/1535-7163.TARG-11-A49
Published: 12 November 2011
View article
Journal Articles

Abstract A47: Circulating tumor cell (CTC) assay development for detection of phosphohistone H3 (pHH3) as a clinical pharmacodynamic (PD) marker for LY2523355, an Eg5 kinesin inhibitor.

Suzane L. Um, S. Betty Yan, Victoria L. Peek, Lei Yan, Xiang S. Ye, Eric H. Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A47.
DOI: https://doi.org/10.1158/1535-7163.TARG-11-A47
Published: 12 November 2011
View article
Journal Articles

Abstract A86: A phase 1 study of LY2523355, an Eg5 inhibitor, administered on Days 1, 2, and 3 with or without pegfilgrastim in patients with advanced malignancy (NCT01214629).

Claire Verschraegen, Roger B. Cohen, Anthony J. Olszanski, Montaser Shaheen, Yuko Nishida, Julie Bauman, Lily Li, John T. Brandt, Aejaz Nasir, Scott M. Hynes, Jennifer K. Leohr, Anna McGlothlin, Eric H. Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A86.
DOI: https://doi.org/10.1158/1535-7163.TARG-11-A86
Published: 12 November 2011
View article